Medical - Devices
Compare Stocks
2 / 10Stock Comparison
VMD vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
VMD vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Care Facilities |
| Market Cap | $353M | $1.60B |
| Revenue (TTM) | $287M | $1.84B |
| Net Income (TTM) | $15M | $59M |
| Gross Margin | 57.5% | 13.3% |
| Operating Margin | 8.2% | 3.0% |
| Forward P/E | 19.2x | 20.8x |
| Total Debt | $16M | $25M |
| Cash & Equiv. | $14M | $161M |
VMD vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Viemed Healthcare, … (VMD) | 100 | 110.6 | +10.6% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VMD vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.95
- Rev growth 20.5%, EPS growth 32.1%, 3Y rev CAGR 24.9%
- 413.5% 10Y total return vs HCSG's -26.8%
HCSG is the clearest fit if your priority is momentum.
- +55.8% vs VMD's +26.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs HCSG's 7.1% | |
| Value | Lower P/E (19.2x vs 20.8x) | |
| Quality / Margins | 5.2% margin vs HCSG's 3.2% | |
| Stability / Safety | Beta 0.95 vs HCSG's 1.12 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +55.8% vs VMD's +26.7% | |
| Efficiency (ROA) | 7.5% ROA vs HCSG's 7.3%, ROIC 11.6% vs 9.0% |
VMD vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VMD vs HCSG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
VMD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCSG is the larger business by revenue, generating $1.8B annually — 6.4x VMD's $287M. Profitability is closely matched — net margins range from 5.2% (VMD) to 3.2% (HCSG). On growth, VMD holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $287M | $1.8B |
| EBITDAEarnings before interest/tax | $46M | $72M |
| Net IncomeAfter-tax profit | $15M | $59M |
| Free Cash FlowCash after capex | $26M | $139M |
| Gross MarginGross profit ÷ Revenue | +57.5% | +13.3% |
| Operating MarginEBIT ÷ Revenue | +8.2% | +3.0% |
| Net MarginNet income ÷ Revenue | +5.2% | +3.2% |
| FCF MarginFCF ÷ Revenue | +9.0% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.5% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +175.0% |
Valuation Metrics
VMD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 24.9x trailing earnings, VMD trades at a 10% valuation discount to HCSG's 27.5x P/E. On an enterprise value basis, VMD's 7.2x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $353M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $356M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 24.89x | 27.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.19x | 20.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7.21x | 22.38x |
| Price / SalesMarket cap ÷ Revenue | 1.31x | 0.87x |
| Price / BookPrice ÷ Book value/share | 2.62x | 3.19x |
| Price / FCFMarket cap ÷ FCF | 29.59x | 11.49x |
Profitability & Efficiency
HCSG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HCSG delivers a 11.8% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $11 for VMD. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to VMD's 0.11x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs VMD's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +10.5% | +11.8% |
| ROA (TTM)Return on assets | +7.5% | +7.3% |
| ROICReturn on invested capital | +11.6% | +9.0% |
| ROCEReturn on capital employed | +13.2% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.11x | 0.05x |
| Net DebtTotal debt minus cash | $2M | -$136M |
| Cash & Equiv.Liquid assets | $14M | $161M |
| Total DebtShort + long-term debt | $16M | $25M |
| Interest CoverageEBIT ÷ Interest expense | 14.61x | 33.02x |
Total Returns (Dividends Reinvested)
HCSG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VMD five years ago would be worth $9,624 today (with dividends reinvested), compared to $7,888 for HCSG. Over the past 12 months, HCSG leads with a +55.8% total return vs VMD's +26.7%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs VMD's -5.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +27.6% | +28.6% |
| 1-Year ReturnPast 12 months | +26.7% | +55.8% |
| 3-Year ReturnCumulative with dividends | -14.6% | +48.6% |
| 5-Year ReturnCumulative with dividends | -3.8% | -21.1% |
| 10-Year ReturnCumulative with dividends | +413.5% | -26.8% |
| CAGR (3Y)Annualised 3-year return | -5.1% | +14.1% |
Risk & Volatility
Evenly matched — VMD and HCSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
VMD is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 1.12x |
| 52-Week HighHighest price in past year | $10.18 | $24.39 |
| 52-Week LowLowest price in past year | $5.93 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +90.5% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 34.7 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 312K | 676K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates VMD as "Buy" and HCSG as "Hold".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | — | $24.50 |
| # AnalystsCovering analysts | 1 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | 20 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.7% | +3.9% |
HCSG leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). VMD leads in 2 (Income & Cash Flow, Valuation Metrics). 1 tied.
VMD vs HCSG: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is VMD or HCSG a better buy right now?
For growth investors, Viemed Healthcare, Inc.
(VMD) is the stronger pick with 20. 5% revenue growth year-over-year, versus 7. 1% for Healthcare Services Group, Inc. (HCSG). Viemed Healthcare, Inc. (VMD) offers the better valuation at 24. 9x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VMD or HCSG?
On trailing P/E, Viemed Healthcare, Inc.
(VMD) is the cheapest at 24. 9x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Viemed Healthcare, Inc. is actually cheaper at 19. 2x.
03Which is the better long-term investment — VMD or HCSG?
Over the past 5 years, Viemed Healthcare, Inc.
(VMD) delivered a total return of -3. 8%, compared to -21. 1% for Healthcare Services Group, Inc. (HCSG). Over 10 years, the gap is even starker: VMD returned +413. 5% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VMD or HCSG?
By beta (market sensitivity over 5 years), Viemed Healthcare, Inc.
(VMD) is the lower-risk stock at 0. 95β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 18% more volatile than VMD relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 11% for Viemed Healthcare, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VMD or HCSG?
By revenue growth (latest reported year), Viemed Healthcare, Inc.
(VMD) is pulling ahead at 20. 5% versus 7. 1% for Healthcare Services Group, Inc. (HCSG). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to 32. 1% for Viemed Healthcare, Inc.. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VMD or HCSG?
Viemed Healthcare, Inc.
(VMD) is the more profitable company, earning 5. 5% net margin versus 3. 2% for Healthcare Services Group, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VMD leads at 7. 7% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — VMD leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VMD or HCSG more undervalued right now?
On forward earnings alone, Viemed Healthcare, Inc.
(VMD) trades at 19. 2x forward P/E versus 20. 8x for Healthcare Services Group, Inc. — 1. 6x cheaper on a one-year earnings basis.
08Which pays a better dividend — VMD or HCSG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is VMD or HCSG better for a retirement portfolio?
For long-horizon retirement investors, Viemed Healthcare, Inc.
(VMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), +413. 5% 10Y return). Both have compounded well over 10 years (VMD: +413. 5%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VMD and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VMD is a small-cap high-growth stock; HCSG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Compare HCSG vs AMSF
AMSF is one of the most direct listed alternatives to HCSG.
Compare VMD vs LINC
LINC overlaps with VMD in an adjacent operating segment worth comparing.
Expand With EHAB + ADUS
EHAB and ADUS are the strongest missing peers across the current compare set.